Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 121
Selected: 0
NCT IDTitle
NCT01034631BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
NCT04069273Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04541173Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT05467891Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT01524991First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
NCT04886531Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT00537173Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
NCT00216073Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
NCT00216060Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT02982720Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
NCT03476174Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
NCT00613626Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT01485874Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
NCT02365766Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
NCT00522665Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
NCT03035630Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
NCT03451331Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
NCT00216125Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
NCT05498272Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT00234494Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
NCT05903092MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
NCT02375672Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
NCT02586610Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
NCT01232881Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
NCT04364048Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
NCT00859339Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
NCT00417248Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
NCT01186458Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT03909334Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT04895046Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
NCT02500901Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT00379912Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
NCT03502746Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
NCT00572572Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
NCT00367601Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
NCT05987644Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT00472589A Biological Sample Collection Protocol of Women With and Without Breast Cancer
NCT03840967A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT00319735Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
NCT03241186Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
NCT00216086Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
NCT05442216Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
NCT00773474Lonafarnib in Metastatic Breast Cancer
NCT00235235A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
NCT03317158Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT00860158Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer